Program
Oral hexavalent reassortant rotavirus attenuated live vaccine
Its studies are mostly in Gastroenteritis, led by Sinovac Biotech.
Furthest: phase 2, since Apr 26, 20252 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 21 open or running | phase 2since Apr 26, 2025 | Apr 22, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2025First study: phase 1 study in Rotavirus GastroenteritisFirst studyNCT06950645 · 100 enrolled · China
- Apr 26, 2025Phase 2 study in Rotavirus GastroenteritisNCT06967272 · 400 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Oral hexavalent reassortant rotavirus attenuated live vaccine”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06967272Rotavirus Gastroenteritis · China | 2 | Recruiting | Jun 15, 2026 | 400 |
| NCT06950645Rotavirus Gastroenteritis · China | 1 | Completed | Dec 21, 2024 | 100 |
How it is read
Names in the registry
- “Oral hexavalent reassortant rotavirus attenuated live vaccine”, 6 entries
Conditions, from the studies’ own filings
- Gastroenteritis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.